Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2)
Authors' conclusion
TACT2 participants were characterized by high use of medication to treat CVD and diabetes and similar baseline metal levels as in the general US population.
Study context
- Population
- Patients with diabetes and prior MI, age 50 years or older, enrolled September 2016–December 2020933 with metals measured
- Participants
- 1,000 patients
- Comparison
- TACT2 participants vs contemporaneous National Health and Nutrition Examination Survey (NHANES) subset
Methodological detailsdouble-masked, placebo-controlled
- Double-masked
- Placebo-controlled
Primary result
As reported in the abstract
baseline
- Blood lead detectable in all participants; median (IQR) 9.19 (6.30, 13.9) µg/L
- Blood cadmium detectable in 97%; median (IQR) 0.28 (0.18, 0.43) µg/L
- Urine cadmium detectable in 97%; median (IQR) 0.30 (0.18, 0.51) µg/g creatinine
- Metal levels largely similar to contemporaneous NHANES subset
Further findings
| Outcome | TACT2 |
|---|---|
| Baseline characteristics | |
| Age, median (IQR) | 67 (60, 72) years |
| Women | 27% |
| White race | 78% |
| BMI, mean (SD) | 32.7 (6.6) kg/m² |
| Type 1 diabetes | 4% |
| Insulin | 46.8% |
| GLP-1 receptor agonists or SGLT2 inhibitors | 22.3% |
| Aspirin, warfarin or P2Y12 inhibitors | 90.2% |
| Statins | 86.5% |
Original publication
Baseline characteristics including blood and urine metal levels in the Trial to Assess Chelation Therapy 2 (TACT2). Am Heart J. Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →